Bain Capital Public Equity Management LLC bought a new position in shares of Idera Pharmaceuticals Inc (NASDAQ:IDRA) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,282,372 shares of the biotechnology company’s stock, valued at approximately $4,816,000. Bain Capital Public Equity Management LLC owned approximately 1.17% of Idera Pharmaceuticals as of its most recent SEC filing.
Several other large investors have also made changes to their positions in the business. California State Teachers Retirement System boosted its position in shares of Idera Pharmaceuticals by 30.0% during the 4th quarter. California State Teachers Retirement System now owns 222,373 shares of the biotechnology company’s stock worth $469,000 after acquiring an additional 51,318 shares in the last quarter. Two Sigma Investments LP acquired a new stake in shares of Idera Pharmaceuticals during the 4th quarter worth approximately $640,000. Deutsche Bank AG boosted its position in shares of Idera Pharmaceuticals by 220.7% during the 4th quarter. Deutsche Bank AG now owns 310,011 shares of the biotechnology company’s stock worth $653,000 after acquiring an additional 213,336 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Idera Pharmaceuticals by 27.8% during the 4th quarter. Geode Capital Management LLC now owns 1,276,263 shares of the biotechnology company’s stock worth $2,692,000 after acquiring an additional 277,566 shares in the last quarter. Finally, Stanley Laman Group Ltd. acquired a new stake in shares of Idera Pharmaceuticals during the 4th quarter worth approximately $1,021,000. Hedge funds and other institutional investors own 36.58% of the company’s stock.
In other Idera Pharmaceuticals news, major shareholder Invest Corp Pillar sold 2,300,000 shares of the firm’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $1.96, for a total value of $4,508,000.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 3,600,000 shares of company stock worth $7,111,000 in the last 90 days. Company insiders own 12.42% of the company’s stock.
Shares of Idera Pharmaceuticals Inc (NASDAQ IDRA) opened at $2.07 on Monday. Idera Pharmaceuticals Inc has a 52-week low of $1.32 and a 52-week high of $2.87. The firm has a market cap of $403.38, a P/E ratio of -6.09 and a beta of 2.17.
Idera Pharmaceuticals (NASDAQ:IDRA) last issued its earnings results on Wednesday, March 7th. The biotechnology company reported ($0.08) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.08). Idera Pharmaceuticals had a negative net margin of 7,315.30% and a negative return on equity of 78.83%. The firm had revenue of $0.17 million for the quarter, compared to analyst estimates of $0.30 million. equities research analysts forecast that Idera Pharmaceuticals Inc will post -0.37 earnings per share for the current fiscal year.
Several research firms recently issued reports on IDRA. Zacks Investment Research lowered shares of Idera Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. HC Wainwright set a $4.00 price target on shares of Idera Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday. BidaskClub upgraded shares of Idera Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, ValuEngine lowered shares of Idera Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the company’s stock. Idera Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $4.83.
Idera Pharmaceuticals Company Profile
Idera Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics for oncology and rare diseases. The Company utilizes two drug discovery technology platforms to design and develop drug candidates, which include Toll-like receptor (TLR) targeting technology and third-generation antisense (3GA) technology.
Receive News & Ratings for Idera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.